SCHEMBL4078174

SCHEMBL4078174

CC1(C)COB(c2cccnc2)OC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.36
HSD17B10 Q99714 3/20 0.36
TSHR P16473 1/20 0.36
SNCA P37840 1/20 0.35
ALDH1A1 P00352 5/20 0.34
CYP2A6 P11509 3/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.34
AR P10275 1/20 0.34
RAB9A P51151 2/20 0.33
POLB P06746 1/20 0.32
ALPL P05186 1/20 0.31
KDM4E B2RXH2 2/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
NPC1 O15118 1/20 0.31
G6PD P11413 1/20 0.31
MAPK1 P28482 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
CHRNB2 P17787 2/20 0.31
CHRNA4 P43681 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2658270 0.83 MEN1 (0.44) ALDH1A1CYP2A6CYP1A2CYP3A4
SCHEMBL21003778 0.83 CYP2A6 (0.32) MAPTHSD17B10TSHRALDH1A1CYP2A6
SCHEMBL13188238 0.82 CYP2A6 (0.46) SNCAALDH1A1CYP2A6CYP1A2CYP3A4
SCHEMBL27949981 0.80 LPL (0.33) MAPTHSD17B10TSHRALDH1A1CYP2A6
SCHEMBL20178054 0.79 SNCA (0.40) MAPTSNCAAR
SCHEMBL20312473 0.79 SNCA (0.35) SNCA
SCHEMBL2938113 0.79 CYP2A6 (0.41) MAPTHSD17B10ALDH1A1CYP2A6CYP1A2
SCHEMBL2274567 0.79 LPL (0.42) SNCA
SCHEMBL3713341 0.79 GRM5 (0.44) CYP2A6CYP1A2CYP3A4CHRNB2CHRNA4
SCHEMBL20312476 0.79 SNCA (0.35) SNCA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12224439-B2 Boron-containing chemicals as cathode additives, Si anode additives, electrolyte additives or separator modifiers for Li-ion batteries ENEVATE CORPORATION (US) 2025-02-11 US claimed
US-20220131148-A1 BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES ENEVATE CORPORATION 2022-04-28 US claimed
US-20200388885-A1 SILICON-BASED ENERGY STORAGE DEVICES WITH LIPO2F2 SALT-CONTAINING ELECTROLYTE FORMULATIONS ENEVATE CORPORATION 2020-12-10 US claimed
US-9663550-B2 Method for preparing abiraterone acetate Wuhan Biocause Pharmaceutical Development Co., Ltd. (CN) 2017-05-30 US claimed
US-20160237109-A1 Method for Preparing Abiraterone Acetate Wuhan Biocause Pharmaceutical Development Co., Ltd. (CN) 2016-08-18 US claimed
US-12224439-B2 Boron-containing chemicals as cathode additives, Si anode additives, electrolyte additives or separator modifiers for Li-ion batteries ENEVATE CORPORATION (US) 2025-02-11 US disclosed
WO-2022093717-A1 BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES ENEVATE CORPORATION (US) 2022-05-05 WO disclosed
US-20220131148-A1 BORON-CONTAINING CHEMICALS AS CATHODE ADDITIVES, SI ANODE ADDITIVES, ELECTROLYTE ADDITIVES OR SEPARATOR MODIFIERS FOR LI-ION BATTERIES ENEVATE CORPORATION 2022-04-28 US disclosed
US-20200388885-A1 SILICON-BASED ENERGY STORAGE DEVICES WITH LIPO2F2 SALT-CONTAINING ELECTROLYTE FORMULATIONS ENEVATE CORPORATION 2020-12-10 US disclosed
US-10504732-B2 Impurity diffusion agent composition and method for manufacturing semiconductor substrate TOKYO OHKA KOGYO CO, LTD. (JP) 2019-12-10 US disclosed
US-20180182624-A1 IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE TOKYO OHKA KOGYO CO., LTD. (JP) 2018-06-28 US disclosed
US-20180182624-A1 IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE TOKYO OHKA KOGYO CO., LTD. (JP) 2018-06-28 US disclosed
US-20150315127-A1 THERAPEUTIC COMPOUNDS UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2015-11-05 US disclosed
US-9024071-B2 Therapeutic compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-05-05 US disclosed
US-9024071-B2 Therapeutic compounds UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2015-05-05 US disclosed
US-7566727-B2 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydro-isoindole-1-one/5,6-dihydro-furo[2,3-c] pyrrol-4-one derivative ligands for alpha 7 nicotinic acetylcholine receptor ASTRAZENECA AB 2009-07-28 US disclosed
US-20070213342-A1 Novel 2-(1-Aza-Bicyclo[2.2.2.]Oct-3-Yl)-2,3-Dihydro-Isoindole-1-One/5,6-Dihydro-Furo[2,3-C] Pyrrol-4-One Derivative Ligands For Alpha 7 Nicotinic Acetylcholine Receptor ASTRAZENECA AB (SE) 2007-09-13 US disclosed
CN-1968951-A Novel 2-(1-aza-bicyclo[2.2.2]oct-3-yl)-2,3-dihydroisoindol-l-one/5,6-dihydro-furo[2,3-c]pyrrol-4one derivatives ligands for alpha 7 nicotinic acetylcholine receptor ASTRAZENECA AB (SE) 2007-05-23 CN disclosed
EP-1737854-A1 NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR AstraZeneca AB (SE) 2007-01-03 EP disclosed
WO-2005100351-A1 NOVEL 2-(1-AZA-BICYCLO[2.2.2]OCT-3-yl)-2,3-DIHYDROISOINDOL-l-ONE/5,6-DIHYDRO-FURO[2,3-c]PYRROL-4ONE DERIVATIVES LIGANDS FOR ALPHA 7 NICOTINIC ACETYLCHOLINE RECEPTOR ASTRAZENECA AB (SE) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180182624-A1 IMPURITY DIFFUSION AGENT COMPOSITION AND METHOD FOR MANUFACTURING SEMICONDUCTOR SUBSTRATE SLC43A1, SAMHD1, SNRPD2 MAPT 1110/4885HSD17B10 3181/4885TSHR 4456/4885
US-20150315127-A1 THERAPEUTIC COMPOUNDS HTR2C, GRK2, GRK3 MAPT 2718/4885HSD17B10 3109/4885TSHR 1441/4885
US-20160237109-A1 Method for Preparing Abiraterone Acetate NR5A1, HSD17B7, CYP17A1 MAPT 4043/4885HSD17B10 111/4885TSHR 1756/4885
US-10504732-B2 Impurity diffusion agent composition and method for manufacturing semiconductor substrate SLC43A1, SAMHD1, SNRPD2 MAPT 1110/4885HSD17B10 3181/4885TSHR 4456/4885
US-20070213342-A1 Novel 2-(1-Aza-Bicyclo[2.2.2.]Oct-3-Yl)-2,3-Dihydro-Isoindole-1-One/5,6-Dihydro-Furo[2,3-C] Pyrrol-4-One Derivative Ligands For Alpha 7 Nicotinic Acetylcholine Receptor CHRNA1, CHRNA7, CHRNE MAPT 3139/4885HSD17B10 2668/4885TSHR 495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.